In a filing, Cullinan Therapeutics Inc revealed its Chief Medical Officer Jones Jeffrey Alan unloaded Company’s shares for reported $41754.0 on Feb 25 ’25. In the deal valued at $8.53 per share,4,895 shares were sold. As a result of this transaction, Jones Jeffrey Alan now holds 174,164 shares worth roughly $1.31 million.
Then, AHMED NADIM sold 12,529 shares, generating $106,872 in total proceeds. Upon selling the shares at $8.53, the President and CEO now owns 430,621 shares.
Before that, Michaelson Jennifer sold 3,756 shares. Cullinan Therapeutics Inc shares valued at $32,039 were divested by the Chief Scientific Officer at a price of $8.53 per share. As a result of the transaction, Michaelson Jennifer now holds 142,004 shares, worth roughly $1.07 million.
UBS initiated its Cullinan Therapeutics Inc [CGEM] rating to a Buy in a research note published on October 24, 2024; the price target was $30. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early May with a ‘”a Buy”‘ rating. William Blair began covering CGEM with “an Outperform” recommendation on April 15, 2024. Wedbush started covering the stock on February 15, 2024. It rated CGEM as “an Outperform”.
Price Performance Review of CGEM
On Tuesday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock fall -0.92% to $7.50. Over the last five days, the stock has lost -9.64%. Cullinan Therapeutics Inc shares have fallen nearly -38.42% since the year began. Nevertheless, the stocks have fallen -55.99% over the past one year. While a 52-week high of $30.19 was reached on 01/03/25, a 52-week low of $7.30 was recorded on 04/01/25. SMA at 50 days reached $9.22, while 200 days put it at $14.17.
Levels Of Support And Resistance For CGEM Stock
The 24-hour chart illustrates a support level at 7.33, which if violated will result in even more drops to 7.16. On the upside, there is a resistance level at 7.61. A further resistance level may holdings at 7.72. The Relative Strength Index (RSI) on the 14-day chart is 31.16, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.72, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.09%. Stochastics %K at 9.59% indicates the stock is a buying.
How much short interest is there in Cullinan Therapeutics Inc?
A steep rise in short interest was recorded in Cullinan Therapeutics Inc stocks on 2025-03-14, dropping by 98717.0 shares to a total of 8.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 8.77 million shares. There was a decline of -1.14%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 15, 2023 when TD Cowen began covering the stock and recommended ‘”an Outperform”‘ rating .
